The first half of 2026 told a familiar story. Stock gains stayed concentrated in a handful of mega-cap names, leaving plenty of quality companies overlooked. Heading into the second half, investors should focus on some low-hanging fruit. Three stocks stand out for their combination of strong themes and meaningful upside potential heading into the back half of the year.
NVIDIA (NASDAQ: NVDA) remains the linchpin of the artificial intelligence trade, even after a choppy few months. Cameco (NYSE: CCJ) sits at the center of a uranium and nuclear energy renaissance that shows no signs of slowing. Boston Scientific (NYSE: BSX) just landed a regulatory win that expands its footprint in cardiac care. Each of these stocks has analyst price targets implying upside of at least 50% over the next 12 months, according to consensus estimates.
Investors chasing the same crowded trades often miss what’s building underneath. These three names offer differentiated exposure: AI infrastructure, energy transition, and medical device innovation. None of them requires betting on a single earnings report to work. Each has a multi-year catalyst path.
Below, we break down the setup for these three stocks, including where the charts stand today. This isn’t a call to buy blindly. It’s a case for putting these names on the watchlist as the second half gets underway.
Three Stocks to Watch: A Pause In NVDA Could Set Up the Next Leg Higher
Have NVIDIA investors simply gotten bored? Shares closed at $197.58 on July 1, down 1.25% on the session and roughly 18% off the May peak near $240. The stock has spent June grinding lower in an orderly pullback rather than a panic decline.
The daily chart shows RSI at 43.26, just below its 14-day moving average of 44.52. That’s neutral-to-soft momentum, not oversold. The MACD line sits at -1.06, below its signal line, confirming the recent downtrend in momentum since the May-June rollover. Price is testing the $195-$200 zone, a level that acted as resistance back in October and November before the stock broke out.
A reclaim of that zone on rising volume would signal the pullback is over. A break below the June low near $193 opens the door to a deeper retest. Either way, consensus analyst targets still imply roughly 60% upside from current levels, underscoring how far sentiment has diverged from Wall Street’s underlying growth assumptions for AI compute demand.
Three Stocks to Watch: CCJ’s Uranium Bull Case Gets a Gut Check
Cameco remains the tip of the spear for the uranium and nuclear energy buildout, but Tuesday’s session was a reminder that the trade isn’t a straight line. Shares dropped 4.39% to $97.39, extending a slide from the February high near $137.
Technicals have turned decisively bearish in the short term. RSI sits at 37.64, below its moving average of 45.54 and approaching oversold territory below 30. The MACD line has fallen to -0.35, with the signal line further negative at -2.25, showing accelerating downside momentum. Volume on the selloff came in above average, a sign of real distribution rather than a thin-market move.
The longer-term structure still matters more than one red day. CCJ remains well above its 2025 base, and the nuclear demand story tied to AI data center power needs hasn’t changed. A stabilization near the $95-$100 support shelf, last tested in June, would be the first sign buyers are stepping back in.
Three Stocks to Watch: BSX Has a Regulatory Win and an Oversold Chart
Boston Scientific just received FDA approval to expand the labeling for its FARAPULSE Pulsed Field Ablation System, widening the eligible patient population for one of its fastest-growing product lines. The news lands at an unusual moment technically: shares have been in a steady downtrend for nearly a year, falling from above $100 to the low $40s.
That decline has pushed RSI down to 28.01, solidly in oversold territory below the 30 threshold, with its moving average close behind at 28.30. More interesting is the MACD, where the MACD line has just crossed above zero to 0.058 while the signal line remains negative at -2.58. That crossover is an early signal that downside momentum may be exhausting itself.
Shares closed at $43.06, up 0.89% on the session, with overnight trading near $43.26. Combined with the FARAPULSE label expansion, the technical setup gives BSX a case as a mean-reversion candidate heading into the second half, assuming the broader downtrend confirms a bottom.
Watching for the Bounce
None of these three stocks is a guaranteed winner. NVDA needs to prove the AI trade still has legs beyond the mega-cap names. CCJ needs uranium prices and utility demand to cooperate through a volatile stretch. BSX needs its oversold bounce to hold up against a year-long downtrend.
What ties them together is a gap between price action and underlying fundamentals. Analysts see substantial upside in all three, and each has a catalyst that doesn’t depend on the broader market cooperating. For investors tired of chasing the same handful of names, these three stocks are worth watching as the second half gets underway.
